"Profit Warning" Junshi Biosciences estimates an annual loss of 873 million RMB, a reduction in loss of 31.9%

Junshi Biosciences (01877.HK) issued a profit warning, expecting a loss of approximately RMB 873 million for the fiscal year 2025 according to Chinese accounting standards, a decrease of RMB 408 million compared to the previous year, representing a reduction of about 31.85%. This is mainly due to the company's ongoing implementation of the "Quality Improvement and Efficiency Enhancement for Returns" action plan, which has significantly improved commercialization capabilities while continuously strengthening cost control and resource focus.

The total operating revenue for the year is approximately RMB 2.5 billion, an increase of 28.32% year-on-year. This is attributed to the growth in sales revenue from commercialized drugs, as the company continues to expand its global commercialization network